Optimal Starting Dose of Ponatinib for Chronic Phase Chronic Myeloid Leukemia
Researchers evaluated the benefit-risk ratio across 3 ponatinib starting doses in patients with chronic phase chronic myeloid leukemia.
Chronic Myeloid Leukemia News
CHRONIC MYELOID LEUKEMIA ADVISOR
Chronic Myeloid Leukemia News
Comorbidities Don’t Hinder Dasatinib’s Activity in Chronic Phase Chronic Myeloid Leukemia
Dasatinib produced responses regardless of comorbidity burden.
New-Generation BCR-ABL TKIs Linked to Increased Risk of Hepatotoxicity in Patients With Chronic Myeloid Leukemia
Researchers sought to determine the risk of hepatotoxicity for patients with CML treated with 4 newer TKIs compared with imitanib.
Changes in Clinical Trial Conduct Prompted by the COVID-19 Pandemic Should Persist
The AACR COVID-19 and Cancer Task Force recommends keeping changes to clinical trial practices that were prompted by the pandemic.
Registry Data Support Use of Ponatinib in CML, Ph+ ALL Resistant or Intolerant to Tyrosine Kinase Inhibitors
An analysis of a registry of patients with CML and Philadelphia chromosome-positive ALL demonstrated that ponatinib is efficacious in those with relapsed or refractory disease.
Therapeutic Drug Monitoring Improved Incidence of Pleural Effusion With Dasatinib for CP-CML
A dose-reduction strategy in patients with CP-CML receiving dasatinib was shown to be feasible and may reduce adverse effects in these patients.
ASCO and Friends: Cancer Patients Should Be Included in COVID-19 Vaccine Trials
A statement recommends including cancer patients and survivors in COVID-19 vaccine trials.
Closing the Gap Between Cancer Patients and Researchers: A Patient Advocate’s Perspective on GRASP
Patient advocate Marlena Murphy provides a patient’s perspective on GRASP.
The Past, Present, and Future of GRASP: Connecting Cancer Researchers, Clinicians, and Patient Advocates
GRASP co-founder Julia Maués explains how the initiative came about and reveals plans for the future.
Underdosing in Patients With Cancer and Obesity: A Thing of the Past?
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.
CML: COVID-19 May Be Fatal in More Than 5% of Patients
The mortality rate was 0.13% in the overall chronic myeloid leukemia cohort.
Response-Based Ponatinib Dosing Appears Effective in Chronic Phase Chronic Myeloid Leukemia
A 45-mg starting dose, reduced to 15 mg, produced the best outcome.
Chronic Myeloid Leukemia: What Your Patients Need to Know
Chronic myeloid leukemia (CML) can be painful and life-threatening if it is not caught in time. How can you educate patients with symptoms or who are newly diagnosed about the detection, symptoms, risk factors, and treatment of CML?
Age and Race May Determine Whether Cancer Patients Access Their Electronic Health Records
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.
How Intermittent Fasting Affects Patients Receiving Tyrosine Kinase Inhibitors for CML
Researchers sought to determine the effects of fasting on drug absorption and efficacy in patients receiving TKIs for chronic myeloid leukemia.
Dasatinib, Nilotinib Effective Second-Line Therapy for Chronic Myeloid Leukemia
Researchers sought to determine whether dasatinib and nilotinib would be effective second-line therapies for patients with chronic phase CML.
BCR-ABL1 Kinetics Associated With Long-Term TFR Status in Patients With Chronic Myeloid Leukemia
Researchers sought to determine key determinants of sustained treatment-free remission in patients with CML who have completed TKI treatment in an attempt to develop strategies that achieve long-term remission.
Case Study Shows Potential Protective Effect of TKI Therapy for Chronic Myeloid Leukemia
A case study with a literature review demonstrates potential antiviral effect of TKI therapy in patients with cancer and COVID-19.
Molecular Response Maintained With Intermittent Tyrosine Kinase Inhibitor Regimen in Patients With CML
Results of the ongoing OPTkIMA study comparing a fixed and a progressive TKI plan in patients with CML is discussed.
American Cancer Society 2021 Statistics Report Shows Continuous Decline in Cancer Mortality Rate, Illuminates Disease-Specific Trends
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...